April 5, 2011
New Therapy for Childhood Leukemia?
(Ivanhoe Newswire) -- An experimental drug lessens symptoms of a rare form of childhood leukemia and offers significant insight into the cellular development of the disease, according to findings from a new UCSF study.
The mouse model research could spearhead the development of new leukemia therapies and paves the way for future clinical trials in humans."Although this drug did not produce a cure, it alleviated the symptoms of leukemia as long as the treatment was continued and delayed the development of a more aggressive disease," senior author Benjamin Braun, M.D., Ph.D., a pediatric cancer specialist at UCSF Benioff Children's Hospital, was quoted as saying. "Maintaining a clinical remission for as long as we can may help patients who don't have other options and perhaps will allow us to approach this disease as a chronic, but manageable, condition."
The study focused on a type of leukemia called juvenile myelomonocytic leukemia, or JMML. It is an aggressive blood cancer that is usually diagnosed in patients younger than 5 and accounts for 1 to 2 percent of all childhood leukemia cases.
Currently, JMML is curable only through bone marrow transplantation, where healthy blood stem cells are extracted from a matched donor and intravenously transplanted into the patient. Still, nearly half of patients relapse after undergoing a transplant, and others are not candidates for transplantation because of advanced illness or the lack of a suitable donor, Braun said.
The researchers treated mice genetically engineered to have JMML with a drug that inhibits a signaling protein called MEK. The drug, known as a MEK inhibitor, blocks just one of the many chemical pathways controlled by Ras. Although several pharmaceutical companies already are developing these drugs, this is the first time a MEK inhibitor has been piloted as a treatment for JMML.
Remarkably, within one week of starting treatment, leukemia symptoms in nearly all of the afflicted mice reversed. Specifically, mice that were treated with the MEK inhibitor produced more red blood cells and fewer white blood cells than untreated mice, and the anemia commonly associated with JMML also disappeared.
According to the researchers, a particularly compelling aspect of the findings is that even after treatment, the majority of the animals' blood was still being produced by the mutant cells that previously caused the disease.
"The most striking aspect of our findings was that the treatment helped the mice not by making the cancer cells go away, but by forcing them to act like normal cells, despite their mutation," first author Natalya Lyubynska, M.D., an internal medicine resident at the University of Michigan, was quoted as saying.
Through the positive effects of treatment, the study also helps clarify the mechanism by which the Ras signaling pathway regulates cell growth and confirms that the MEK protein plays a key role in the development of JMML.
"It appears that Ras causes disease, in part, by producing an imbalance of the kinds of cells made in the bone marrow, and that inhibiting MEK can reverse that process," Braun said. "We hope one day to improve on these results by finding a way to completely eliminate leukemia cells. At the same time, we are also learning more about how bone marrow makes the right numbers of each type of cell every day."
SOURCE: Science Translational Medicine, published online March 30, 2011